Rx-360 announces Mark Paxton as new CEO
Rx-360’s first CEO will lead the consortium to its next phase of growth.
Rx-360 has appointed Mark S. Paxton to the position of CEO of the international pharmaceutical supply chain consortium. This appointment follows the successful growth of the organization since its foundation in 2009 in the aftermath of the adulterated heparin tragedy. Mark will provide leadership to a vibrant organization of 300 volunteers from over 100 institutions that are organized in 17 working groups with activities in the US, Europe, China and India.
Rx-360’s first CEO will lead the consortium and its membership in executing the Board’s Strategic Plan, expanding its membership and creating global awareness of Rx-360’s central mission: To protect patient safety by sharing information and developing processes related to the integrity of the healthcare supply chain and the quality of materials within the supply chain.
“I am delighted to welcome Mark to Rx-360. We have in Mark the leader that will take the consortium to its next phase of growth so that we may harness the passion of all those of us in the Industry that put the patient ahead of everything else,” says Guy Villax, Rx-360 Chair.
Mark comes to Rx-360 from the FDA where he led an international Strategic Program focused on medical product quality and supply chain security under Asia-Pacific Economic Cooperation (APEC), a multi-lateral forum of governments to promote sustainable economic growth within the Asia-Pacific region.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.